Breast Cancer Chemotherapy – Here Is What Happened When Outrageous Prices Met The Free Market

Breast Cancer Chemotherapy – Here Is What Happened When Outrageous Prices Met The Free Market

Byadmin2

Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet.

Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at over $70,000 per patient. How did it remain so expensive for so long? And what happened recently to bring the price down almost 60%?

I have a one word answer to both questions: biosimilars! Read more here

Similar Posts

Is Behavioral Economics the Death of Living Wills?

Byadmin

As a physician who conducts research on decision-making, I have been asked many times: What does behavioral economics teach us about the role of living wills in medical care? Famed behavioral economist Dick Thaler recently opined on this topic in the New York Times, stating his support for a “requirement that all patients meet with their…

The Question Isn't Whether We Are Overdiagnosing Cancer, But How Much

Byadmin

Medical experts now agree that as a result of aggressive screening programs, we have an epidemic of cancer overdiagnosis in the United States. With mammograms finding tiny cancers and PSA tests discovering unpalpable prostate cancers, we are now unearthing some cancers too early for our own good. What do experts mean by “overdiagnosis,” you ask?…

|

What would you do, doc?

Byadmin

A bunch of media outlets are beginning to report on a new study of mine (conducted with a couple of great colleagues) in which we found that docs choose different treatments for themselves than they recommend to their patients. Kinda scary stuff. This Marketplace report is worth listening to. Check out the ‘News and Press’ page for links to some of the other reports.